About
Technology
Issues
FAQ
Search
Profile
Top Authors
Prolific Authors
Top Journals
Main Disciplines
Main Topics
Most Cited Articles
Scientometrics
Avg Impact Factor
★★
Articles
★★★
Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Schools
›
Department of Clinical Hematology
›
top-articles
Department of Clinical Hematology
8
(top 5%)
papers
316
(top 5%)
citations
4
(top 5%)
h
-index
7
(top 5%)
g
-index
8
all documents
327
doc citations
165
citing journals
Top Articles
#
Title
Journal
Year
Citations
1
A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies
Blood
2016
231
2
Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report
Blood
2017
73
3
Randomized phase III study comparing an early PET driven treatment de-escalation to a not PET-monitored strategy in patients with advanced stages Hodgkin lymphoma: Final analysis of the AHL2011 LYSA study.
Journal of Clinical Oncology
2018
12
4
THE RISK OF TRANSFORMATION OF FOLLICULAR LYMPHOMA “TRANSFORMED” BY RITUXIMAB: THE ARISTOTLE STUDY PROMOTED BY THE EUROPEAN LYMPHOMA INSTITUTE
Hematological Oncology
2017
8
5
First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin’s lymphoma
Bone Marrow Transplantation
2017
1
6
PRELIMINARY RESULTS OF A PHASE 1B STUDY OF TIRABRUTINIB (GS‐4059/ONO‐4059) IN COMBINATION WITH ENTOSPLETINIB IN PATIENTS WITH B‐CELL MALIGNANCIES
Hematological Oncology
2017
1
7
Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of GS-4059 in Combination with Idelalisib in Subjects with B-Cell Malignancies
Blood
2016
1
8
Preliminary results of a phase Ib study of GS-4059 in combination with entospletinib in patients with B-cell malignancies.
Journal of Clinical Oncology
2017
0
site/software ©
exaly
; All materials licenced under
CC by-SA
.